文献速递胸部肿瘤

体重指数与阿替利珠单抗治疗晚期非小细胞肺癌总生存的关联

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究汇总4项国际多中心试验的2110例晚期NSCLC患者个体数据,其中1434例接受阿替利珠单抗、676例接受多西他赛。结果显示阿替利珠单抗组BMI与OS呈线性关联,肥胖(BMI≥30)与OS显著改善相关,而多西他赛组无此关联;PD-L1高表达亚组中关联最强,治疗相关不良事件与BMI无关。

要点

  • 阿替利珠单抗治疗晚期NSCLC时,BMI升高与OS改善呈线性关联。
  • 肥胖(BMI≥30)与阿替利珠单抗组OS显著改善相关,多西他赛组无此关联。
  • PD-L1高表达亚组中BMI与OS/PFS关联最强,治疗相关不良事件与BMI无关。

核心结论

  • 高BMI似乎独立与阿替利珠单抗治疗NSCLC患者生存改善相关,提示未来免疫检查点抑制剂试验可将基线BMI作为分层因素。

研究设计与样本

  • 汇总4项国际多中心临床试验的个体患者数据,包括2项单臂2期试验(BIRCH、FIR)和2项随机试验(POPLAR为2期、OAK为3期)。
  • 共2110例晚期NSCLC患者纳入分析,其中1434例接受阿替利珠单抗(中位年龄64岁,890例男性),676例接受多西他赛(中位年龄63岁,419例男性)。

主要发现

  • 阿替利珠单抗组BMI升高与OS呈线性关联,肥胖(BMI≥30)与OS显著改善相关,而多西他赛组无此关联。
  • PD-L1最高表达类别(≥50%肿瘤细胞或≥10%肿瘤浸润免疫细胞,n=436)中,肥胖组OS的HR为0.36(95%CI 0.21-0.62),超重组为0.69(95%CI 0.48-0.98)。
  • 同一PD-L1最高表达类别中,肥胖组PFS的HR为0.68(95%CI 0.49-0.94),超重组为0.72(95%CI 0.56-0.92)。
  • 治疗相关不良事件与BMI无关联。

临床怎么用

  • 基线BMI可能作为接受阿替利珠单抗治疗的晚期NSCLC患者的预后参考因素。
  • 未来免疫检查点抑制剂临床试验可考虑将基线BMI作为分层因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non-small cell lung cancer treated with atezolizumab remains unknown. OBJECTIVE: To examine whether BMI is associated with survival outcomes and adverse events in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab. DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis of individual patient-level data from 4 international, multicenter clinical trials was performed. Two were single-arm phase 2 trials (BIRCH [data cutoff of May 28, 2015] and FIR [data cutoff of January 7, 2015]), and 2 were 2-arm randomized clinical trials (POPLAR [phase 2; data cutoff of May 8, 2015] and OAK [phase 3; data cutoff of July 7, 2016]). Patients with advanced NSCLC previously untreated or treated with at least 1 line of systemic therapy, with measurable disease and good organ function and without contraindications for chemotherapy or immune checkpoint inhibitor therapy, were included in these trials. Data analyses were performed from February 28, 2019, to September 30, 2019. INTERVENTIONS: The control group was treated with docetaxel once every 3 weeks until disease progression or unacceptable toxic effects occurred in POPLAR and OAK. The experimental group was treated with atezolizumab once every 3 weeks until disease progression or unacceptable toxic effects occurred in all available trials. MAIN OUTCOMES AND MEASURES: Association between BMI and overall survival (OS), progression-free survival (PFS), and treatment-related adverse events. Intention-to-treat analysis was conducted. RESULTS: Adequate data were available for 2110 patients from a total pool of 2261 across 4 trials. Of those 2110, 1434 patients (median age, 64 years [range, 57-70 years]; 890 men [62%]) received atezolizumab and 676 patients (median age, 63 years[range, 57-69 years]; 419 men [62%]) received docetaxel. There was a linear association between increasing BMI and OS in patients treated with atezolizumab. Obesity (BMI ≥30 [calculated as weight in kilograms divided by height in meters squared]) was associated with significantly improved OS in patients treated with atezolizumab, but not in those who received docetaxel after adjusting for confounding variables. The association between BMI and OS/PFS was the strongest in the high PD-L1 expression subgroup. Overall survival for patients with the highest category of PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells; n = 436) had hazard ratios of 0.36 (95% CI, 0.21-0.62) for the group with obesity and 0.69 (95% CI, 0.48-0.98) for the group with overweight. Patients with the highest category of PD-L1 expression had PFS hazard ratios of 0.68 (95% CI, 0.49-0.94) for the group with obesity and 0.72 (95% CI, 0.56-0.92) for the group with overweight. Treatment-related adverse events were not associated with BMI. CONCLUSIONS AND RELEVANCE: High BMI appears to be independently associated with improved survival with atezolizumab in patients with NSCLC, raising the possibility that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kichenadasse G, Miners JO, Mangoni AA, et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2020. PMID: 31876896. doi:10.1001/jamaoncol.2019.5241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。